You are here

Scheduling delegate's interim decisions and invitation for further comment: ACCS/ACMS, March and July 2017

Scheduling medicines and poisons

15 September 2017

Book pagination

1. Summary of delegate's interim decisions

Advisory Committee on Medicines Scheduling (ACMS #21)

Summary of delegate's interim decisions
Substance Interim decision
Sildenafil The delegate's interim decision is that the current scheduling of sildenafil remains appropriate.
Vardenafil The delegate's interim decision is that the current scheduling of vardenafil remains appropriate.
Ibuprofen combined with paracetamol The delegate's interim decision is that the current scheduling of ibuprofen combined with paracetamol remains appropriate.
Esomeprazole

Schedule 4 – Amend Entry

ESOMEPRAZOLE except when included in Schedule 2.

Schedule 3 – Delete Entry

Schedule 2 – Amend Entry

ESOMEPRAZOLE in oral preparations containing 20 mg or less per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply.

The proposed implementation date is 1 February 2018.
Stiripentol

Appendix K – New Entry

STIRIPENTOL

The proposed implementation date is 1 February 2018.

Book pagination